

# The analgesic evaluation of gabapentin for arthroscopy

# A meta-analysis of randomized controlled trials

Feiri Huang, MD<sup>a</sup>, Zhifang Yang, MD<sup>a</sup>, Zhongliang Su, MD<sup>a</sup>, Xiaosheng Gao, MD<sup>b,\*</sup>

#### Abstract

**Introduction:** The efficacy of gabapentin for pain management of arthroscopy remains controversial. We conduct a systematic review and meta-analysis to explore the influence of gabapentin versus placebo on the postoperative pain intensity of arthroscopy.

**Methods:** We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through April 2020 for randomized controlled trials assessing the effect of gabapentin versus placebo on pain control of arthroscopy. This meta-analysis is performed using the random-effect model.

**Results:** Five randomized controlled trials are included in the meta-analysis. Overall, compared with control group for arthroscopy, gabapentin remarkably decreases pain scores at 24 hour (standard mean difference [SMD]=-0.68; 95% confidence interval [CI]=-1.15 to -0.02; P=.21), analgesic consumption (SMD = -18.24; 95% CI=-24.61 to -11.88; P<.00001), nausea and vomiting (OR = 0.42; 95% CI=0.21 to 0.84; P=.01), but has no obvious influence on pain scores at 6h (SMD=-1.30; 95% CI=-2.92 to 0.31; P=.11) or dizziness (OR=1.12; 95% CI=0.56 to 2.24; P=.75).

Conclusions: Gabapentin is effective for pain control after arthroscopy.

Abbreviations: CI = confidence interval, RCTs = randomized controlled trials, SMD = standard mean difference.

Keywords: arthroscopy, gabapentin, meta-analysis, pain management, randomized controlled trials

# 1. Introduction

Arthroscopy has been extensively developed for the diseases of shoulder, knee, and hip.<sup>[1–4]</sup> Moderate to severe pain commonly occurs after arthroscopic surgery, and results from insertion of arthroscopic instruments into the joint, bone removal, soft tissue dissection, and distention.<sup>[5–9]</sup> Multimodal analgesia is developed to target the routes of nerves and various neurotransmitters to inhibit hyperalgesia and nociception.<sup>[10]</sup> It may also improve inflammatory and neurogenic conditions.<sup>[11]</sup>

Ethics approval and consent to participate was not applicable.

Consent for publication was not applicable.

The authors have no funding and conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

<sup>a</sup> Department of Orthopedics, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, <sup>b</sup> Department of Orthopedics, Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, P.R. China.

<sup>\*</sup> Correspondence: Xiaosheng Gao, Postal address: NO.311 Yingpan Road, Kaifu District, Wenzhou, Zhejiang Province, P.R. China (e-mail: gxs\_129@163.com).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Huang F, Yang Z, Su Z, Gao X. The analgesic evaluation of gabapentin for arthroscopy: a meta-analysis of randomized controlled trials. Medicine 2021;100:20(e25740).

Received: 6 July 2020 / Received in final form: 3 April 2021 / Accepted: 7 April 2021

http://dx.doi.org/10.1097/MD.00000000025740

Gabapentin was used as an anti-epileptic drug and was subsequently applied for acute and chronic pain associated with different diseases such as post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia and various headaches.<sup>[12]</sup> It acts through binding to the alpha 2-delta-subunit of voltage-gated calcium channels and inhibiting the release of nociceptive neurotransmitters including glutamates, P-substance and norepinephrine from presynaptic afferent neurons.<sup>[13]</sup> The anti-hyperalgesic feature of gabapentin may focus on the reduction of pathologic postoperative pain significantly and decrease the need to opioids.<sup>[15]</sup> In contrast, a systematic narrative review of 22 randomized clinical trial studies indicated that gabapentin as a single dose preemptive analgesia did not reduce pain and opioid consumption.<sup>[16,17]</sup>

The application of gabapentin for the pain management of arthroscopy is not fully explored, and several studies reported the conflicting results.<sup>[18–20]</sup> With accumulating evidence, we therefore perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to explore the efficacy and safety of gabapentin in patients with arthroscopy.

# 2. Materials and methods

Ethical approval and patient consent are not required because this is a systematic review and meta-analysis of previously published studies. The systematic review and meta-analysis are conducted and reported in adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).<sup>[21,22]</sup>

### 2.1. Search strategy and study selection

Two investigators have independently searched the following databases (inception to April 2020): PubMed, EMbase, Web of

Editor: Giovanni Tarantino.

science, EBSCO, and Cochrane library databases. The electronic search strategy is conducted using the following keywords: gabapentin, and arthroscopy. We also check the reference lists of the screened full-text studies to identify other potentially eligible trials.

The inclusive selection criteria are as follows:

- (1) study design is RCT;
- (2) population are patients undergo arthroscopy;
- (3) intervention treatments are pregabalin versus placebo.

#### 2.2. Data extraction and outcome measures

We have extracted the following information: author, number of patients, age, female, body weight, duration of surgery and detail methods in each group and so on. Data have been extracted independently by two investigators, and discrepancies are resolved by consensus. We also contact the corresponding author to obtain the data when necessary.

The primary outcomes are pain scores at 6 hour and 24 hour. Secondary outcomes include analgesic consumption, dizziness, nausea, and vomiting.

#### 2.3. Quality assessment in individual studies

Methodological quality of the included studies is independently evaluated using the modified Jadad scale.<sup>[23]</sup> There are 3 items for Jadad scale: randomization (0-2 points), blinding (0-2 points), dropouts and withdrawals (0-1 points). The score of Jadad Scale varies from 0 to 5 points. An article with Jadad score $\leq 2$  is considered to be of low quality. If the Jadad score  $\geq 3$ , the study is thought to be of high quality.<sup>[24]</sup>

#### 2.4. Statistical analysis

We estimate the standard mean difference (SMD) with 95% confidence interval (CI) for continuous outcomes (pain scores at 6 hour and 24 hour, analgesic consumption) and odd ratio (OR) with 95% CIs for dichotomous outcomes (dizziness, nausea and vomiting). The random-effects model is used regardless of heterogeneity. Heterogeneity is reported using the  $I^2$  statistic, and  $I^2 > 50\%$  indicates significant heterogeneity.<sup>[22,25]</sup> Whenever significant heterogeneity is present, we search for potential sources of heterogeneity via omitting one study in turn for the meta-analysis or performing subgroup analysis. All statistical analyses are performed using Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford).

# 3. Results

#### 3.1. Literature search, study characteristics and quality assessment

A detailed flowchart of the search and selection results is shown in Figure 1. 261 potentially relevant articles are identified initially. Finally, five RCTs that meet our inclusion criteria are included in the meta-analysis.<sup>[18–20,26,27]</sup>

The baseline characteristics of the five eligible RCTs in the meta-analysis are summarized in Table 1. The three studies are published between 2006 and 2016, and total sample size is 346. The doses of gabapentin include 300 mg,<sup>[26]</sup> 600 mg,<sup>[18,19]</sup> or 800 mg<sup>[27]</sup> before the surgery. Another included RCT involve 300 mg of gabapentin before surgery, then twice a day for 2 days.<sup>[20]</sup>

Among the five studies included here, two studies report pain scores at 6 h,<sup>[18,19]</sup> three studies report pain scores at 24 hour,<sup>[18-20]</sup> two studies report analgesic consumption,<sup>[18,19]</sup> four studies report dizziness,<sup>[18-20,26]</sup> as well as four studies report nausea and vomiting.<sup>[18,19,26,27]</sup> Jadad scores of the five included studies vary from 3 to 5, and all five studies are considered to be high-quality ones according to quality assessment.

#### 3.2. Primary outcomes: pain scores at 6 hour and 24 hour

These outcome data are analyzed with the random-effects model, and compared to control group for arthroscopy, gabapentin shows no obvious impact on pain scores at 6 hour (SMD = -1.30; 95% CI = -2.92 to 0.31; *P* = .11) with significant heterogeneity among the studies ( $I^2$  = 93%, heterogeneity *P* = .0002) (Fig. 2), but is associated with significantly reduced pain scores at 24 hour (SMD = -0.68; 95% CI = -1.15 to -0.02; *P* = .21) with no heterogeneity among the studies ( $I^2$  = 0%, heterogeneity *P* = .53) (Fig. 3).

#### 3.3. Sensitivity analysis

Significant heterogeneity is observed among the included studies for pain scores at 6 hour. There are just two included RCTs, so we do not perform sensitivity analysis via omitting one study in turn to detect the heterogeneity.


#### 3.4. Secondary outcomes

In comparison with control group for arthroscopy, gabapentin can substantially reduce analgesic consumption (SMD = -18.24; 95% CI = -24.61 to -11.88; P < .00001; Fig. 4), but exhibits no obvious impact on dizziness (OR = 1.12; 95% CI = 0.56 to 2.24; P=0.75; Fig. 5). In addition, the incidence of nausea and vomiting is found to be lower in gabapentin group than that in control group (OR = 0.42; 95% CI = 0.21 to 0.84; P = .01; Fig. 6).

#### 4. Discussion

Many methods have been developed to reduce postoperative pain after arthroscopic surgery, and include infiltration of local anesthetic, nerve block and interscalene block.<sup>[28–30]</sup> However, they are limited by procedural difficulties and complications inherent in their invasive nature.<sup>[31]</sup> Non-steroidal anti-inflammatory drugs and opioid drugs are commonly used for the postoperative pain control, but may lead to nausea, vomiting and gastrointestinal bleeding. Thus, multimodal analgesia is developed to reduce these opioid-related adverse effect.<sup>[32]</sup>

Gabapentinoids were found to interact with other analgesics additively or synergistically to decrease inflammatory hyperalgesia, and decrease opioid consumption.<sup>[33,34]</sup> Gabapentin on postoperative pain was studied in different surgical interventions, and showed obvious decrease in pain intensity and opioid consumption in hysterectomy and spinal surgery.<sup>[35]</sup> In orthopedic and musculoskeletal surgeries, the pain intensity and opioid consumption at 24 hour follow-up visit was significantly reduced among patients taking gabapentin.<sup>[27,36–38]</sup> Arthroscopic surgery, as a minimally-invasive procedure, has been increasing, but only limited numbers of studies examining the effectiveness of gabapentin in arthroscopic surgeries.<sup>[20,26,27]</sup> Our meta-analysis includes five RCTs involving 346 patients, and the results suggest that gabapentin is associated with substantially reduced pain



scores at 24 hour and analgesic consumption for arthroscopy, but has no remarkable influence on pain scores at 6 hour.

The efficacy in administration of gabapentin as a preemptive analgesic reported may be caused by the differences in gabapentin dosages, the time of the administration of gabapentin, being a single dose or multiple doses, and anesthesia method. The included RCTs reported different doses of gabapentin including 300 mg,<sup>[26]</sup> 600 mg,<sup>[18,19]</sup> or 800 mg<sup>[27]</sup> before the surgery, as well as 300 mg of gabapentin before surgery, then twice a day for 2 days.<sup>[20]</sup> A meta-analysis of 1151 patients (614 patients taking gabapentin in 16 RCTs) included three categories according to the gabapentin dosages: A. a single dose of 1200 mg; B. a single

dose less than 1200 mg; C. multiple dose of less than 1200 mg. The results revealed that patients with a single dose of gabapentin experienced significantly less pain than the placebo group, and gabapentin group results in significantly more sedation, but less vomiting and pruritus.<sup>[39]</sup> 600 mg dosage of gabapentin was more effective than 300 mg dosage and has the same effectiveness as higher dosages (900 and 1200 mg) in reducing pain intensity and total opioid consumption.<sup>[40]</sup> Repeated multi-doses of gabapentin increase the side effects especially sedation.<sup>[18]</sup> These recommend a single dose of 600 mg gabapentin for the pain control after arthroscopy, but more studies should be conducted to confirm this issue.

# Table 1

#### Characteristics of included studies.

			Gabapentin group						Control group					
NO.	Author	Number	Age (yr)	Female (n)	Weight (kg)	Duration of surgery (min)	Methods	Number	Age (yr)	Female (n)	Weight (kg)	Duration of surgery (min)	Methods	Jada scores
1	Mardani-Kivi 2016	38	30.2±5	11	68.2±1.8	$46.9 \pm 10.7$	gabapentin 600 mg, 2 h before surgery	38	$28.3 \pm 4.4$	8	67.4±11.3	$43.9\pm9.5$	placebo	4
2	Kivi 2013	57	$32.2 \pm 9.3$	8	$74.9 \pm 9.4$	$40 \pm 10$	gabapentin 600 mg	57	$30.5 \pm 10.2$	6	$73.6 \pm 8.5$	$36 \pm 7$	placebo	4
3	Spence 2011	26	31.8±10.48	4	-	_	300 mg of gabapentin 1 h before surgery, then twice a day for 2 d	31	31.51±8.9	5	_	_	placebo	3
4	Bang 2010	23	$56.3 \pm 8.5$	14	63.9±11.8	$104.7 \pm 35.8$	gabapentin 300 mg, 2 h before surgery	23	$59.5 \pm 6.2$	15	64.2±8.4	98.7±23.7	placebo	4
5	Adam 2006	27	43±18	9	70±12	57±31	gabapentin 800 mg, 2 h before surgery	26	47±15	8	74±13	57±27	placebo	4






Figure 2. Forest plot for the meta-analysis of pain scores at 6h.

Std. Mean Difference	SE		td. Mean Difference IV, Random, 95% Cl		and the second	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
-1.3	0.62	14.8%	-1.30 [-2.52, -0.08]			and the billing of a	
-0.6	0.28	72.8%	-0.60 [-1.15, -0.05]				
-0.38	0.68	12.3%	-0.38 [-1.71, 0.95]				
		100.0%	-0.68 [-1.15, -0.21]		+		
0.00; Chi <sup>2</sup> = 1.28, df = 2	(P = 0	.53); l <sup>2</sup> = 09	%	+	1		
Z = 2.83 (P = 0.005)		-4	-2 Favours [experimental]	Favours [control]	4		
	-1.3 -0.6 -0.38 0.00; Chi² = 1.28, df = 2	-1.3 0.62 -0.6 0.28 -0.38 0.68 0.00; Chi² = 1.28, df = 2 (P = 0	Std. Mean Difference SE Weight   -1.3 0.62 14.8%   -0.6 0.28 72.8%   -0.38 0.68 12.3%   100.0%   0.00; Chi² = 1.28, df = 2 (P = 0.53); l² = 0	-1.3 0.62 14.8% -1.30 [-2.52, -0.08] -0.6 0.28 72.8% -0.60 [-1.15, -0.05] -0.38 0.68 12.3% -0.38 [-1.71, 0.95] 100.0% -0.68 [-1.15, -0.21] 0.00; Chi <sup>2</sup> = 1.28, df = 2 (P = 0.53); l <sup>2</sup> = 0%	Std. Mean Difference SE Weight IV. Random. 95% CI   -1.3 0.62 14.8% -1.30 [-2.52, -0.08]   -0.6 0.28 72.8% -0.60 [-1.15, -0.05]   -0.38 0.68 12.3% -0.38 [-1.71, 0.95]   100.0% -0.68 [-1.15, -0.21] -0.60; Chi² = 1.28, df = 2 (P = 0.53); l² = 0% -4	Std. Mean Difference SE Weight IV. Random. 95% CI IV. Random.   -1.3 0.62 14.8% -1.30 [-2.52, -0.08] -0.60 -0.6	Std. Mean Difference SE Weight IV. Random. 95% CI IV. Random. 95% CI   -1.3 0.62 14.8% -1.30 [-2.52, -0.08] -0.60 <



4





	Gabapentin	<b>Control group</b>			<b>Odds Ratio</b>	Odds Ra			•		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	6	5% CI			
Adam 2006	7	27	15	26	36.9%	0.26 [0.08, 0.82]			_		
Bang 2010	7	23	11	23	34.0%	0.48 [0.14, 1.60]			-		
Kivi 2013	3	57	4	57	20.8%	0.74 [0.16, 3.45]			•	- 10 J	
Mardani-Kivi 2016	1	38	2	38	8.3%	0.49 [0.04, 5.60]		-	-		
Total (95% CI)		145		144	100.0%	0.42 [0.21, 0.84]		-			
Total events	18		32								
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup> = 1.	26, df = 3	(P = 0.74)	; 12 = 09	6			1	1.15	10	100
Test for overall effect:		0.01 Favo	0.1 ours [experime	ental] Favo	10 urs [control]	100					

Gabapentin 2 hours preoperatively is recommended to administer because it can achieve the maximum plasma concentration 2-3h after taking the drug. Since gabapentin has no hepatic metabolism and is excreted without change through the kidneys, gabapentin is well tolerant.<sup>[18,41]</sup> In this meta-analysis, gabapentin shows no increase in dizziness, but is associated with the decrease in nausea and vomiting, which may be derived from the reduction of analgesic consumption after the surgery. This metaanalysis has several potential limitations. Firstly, our analysis is based on five RCTs, and all of them have a relatively small sample size (n < 100). Overestimation of the treatment effect is more likely in smaller trials compared with larger samples. Next, there is significant heterogeneity for pain scores at 6 hour, which may be caused by different methods of gabapentin and operation procedures. Finally, it is not feasible to perform the meta-analysis of some important index such as pain scores at longer follow up time and perform the subgroup analysis based on dosages.

# 5. Conclusions

Gabapentin is effective and safe to relieve the pain after arthroscopy.

#### Author contributions

Conceptualization: Feiri Huang. Data curation: Feiri Huang, Xiaosheng Gao. Formal analysis: Feiri Huang, Xiaosheng Gao. Methodology: Zhifang Yang. Software: Zhongliang Su. Writing – original draft: Xiaosheng Gao. Writing – review & editing: Xiaosheng Gao.

# References

- Maradit Kremers H, Schilz SR, Van Houten HK, et al. Trends in utilization and outcomes of hip arthroscopy in the United States Between 2005 and 2013. J Arthroplast 2017;32:750–5.
- [2] Kandil A, Safran MR. Hip arthroscopy: a brief history. Clin Sports Med 2016;35:321–9.
- [3] Brignardello-Petersen R, Guyatt GH, Buchbinder R, et al. Knee arthroscopy versus conservative management in patients with degenerative knee disease: a systematic review. BMJ open 2017;7:e016114.
- [4] Gil JA, Gunaseelan V, DeFroda SF, et al. Risk of prolonged opioid use among opioid-naïve patients after common shoulder arthroscopy procedures. Am J Sports Med 2019;47:1043–50.
- [5] Botser IB, Smith TWJr, Nasser R, et al. Open surgical dislocation versus arthroscopy for femoroacetabular impingement: a comparison of clinical outcomes. Arthroscopy 2011;27:270–8.
- [6] C. 29162135Li, J. Qu, Efficacy of dexmedetomidine for pain management in knee arthroscopy: a systematic review and meta-analysis, Medicine 96(43) (2017) e7938.
- [7] Tepolt FA, Bido J, Burgess S, et al. Opioid overprescription after knee arthroscopy and related surgery in adolescents and young adults. Arthroscopy 2018;34:3236–43.
- [8] Tong D, Chung F. Postoperative pain control in ambulatory surgery. Surg Clin North Am 1999;79:401–30.
- [9] Chen X, Mou X, He Z, et al. The effect of midazolam on pain control after knee arthroscopy: a systematic review and meta-analysis. J Orthop Surg Res 2017;12:179.
- [10] Block BM, Liu SS, Rowlingson AJ, et al. Efficacy of postoperative epidural analgesiaa meta-analysis. JAMA 2003;290:2455–63.
- [11] Kong VKF, Irwin MG. Gabapentin: a multimodal perioperative drug? Br J Anaesth 2007;99:775–86.
- [12] Kukkar A, Bali A, Singh N, et al. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res 2013;36:237–51.
- [13] Baillie JK, Power I. The mechanism of action of gabapentin in neuropathic pain. Curr Opin Investig Drugs 2006;7:33–9.
- [14] J. Dirks, M.D., Birgitte B. Fredensborg, M.D., D. Christensen, M.D., Ph. D., Jonna S. Fomsgaard, M.D., H. Flyger, M.D., Ph.D., Jørgen B. Dahl, M.D., Ph.D., A Randomized Study of the Effects of Single-dose Gabapentin versus Placebo on Postoperative Pain and Morphine

Consumption after Mastectomy, Anesthesiology: The Journal of the American Society of Anesthesiologists 97(3) (2002) 560-564-560-564.

- [15] Dahl JB, Mathiesen O, Møiniche S. 'Protective premedication': an option with gabapentin and related drugs? Acta Anaesthesiologica Scandinavica 2004;48:1130–6.
- [16] Turan A, Karamanlioğlu B, Memiş D, et al. The analgesic effects of gabapentin after total abdominal hysterectomy. Anesth Analg 2004; 98:1370–3.
- [17] Dauri M, Faria S, Gatti A, et al. Gabapentin and pregabalin for the acute post-operative pain management. A Systematic-narrative Review of the Recent Clinical Evidences, Current drug targets 2009;10:716–33.
- [18] Mardani-Kivi M, Karimi Mobarakeh M, Keyhani S, et al. Arthroscopic bankart surgery: does gabapentin reduce postoperative pain and opioid consumption? A triple-blinded randomized clinical trial, Orthopaedics & Traumatology: Surgery & Research 2016;102:549–53.
- [19] Kivi M, Mobarakeh M, Keyhani S, et al. Is gabapentin effective on pain management after ar- throscopic anterior cruciate ligament reconstruction? A Triple Blinded Randomized Controlled Trial, The Archives of Bone and Joint Surgery 2013;1:18–22.
- [20] Spence D, Goff J, Mohan E, et al. Perioperative administration of gabapentin for shoulder arthroscopy: a prospective, randomized, doubleblind, placebo-controlled study. AANA J 2011;79(4 Suppl):S43–50.
- [21] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
- [22] Zhao J, Huang W, Zhang S, et al. Efficacy of glutathione for patients with cystic fibrosis: a meta-analysis of randomized-controlled studies. Am J Rhinol Allerg 2019;1945892419878315.
- [23] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
- [24] Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in metaanalyses. Ann Intern Med 2001;135:982–9.
- [25] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
- [26] Bang SR, Yu SK, Kim TH. Can gabapentin help reduce postoperative pain in arthroscopic rotator cuff repair? A Prospective, Randomized, Double-Blind Study, Arthroscopy: The Journal of Arthroscopic & Related Surgery 2010;26(9, Supplement):S106–11.
- [27] Adam F, Ménigaux C, Sessler D I, et al. A single preoperative dose of gabapentin (800 milligrams) does not augment postoperative analgesia

in patients given interscalene brachial plexus blocks for arthroscopic shoulder surgery. Anesth Analg 2006;103:1278-82.

- [28] Ciccone II WJ, Busey TD, Weinstein DM, et al. Assessment of pain relief provided by interscalene regional block and infusion pump after arthroscopic shoulder surgery. Arthroscopy 2008;24:14–9.
- [29] Price D. The shoulder block: a new alternative to interscalene brachial plexus blockade for the control of postoperative shoulder pain. Anaesth Intensive Care 2007;35:575–81.
- [30] Delaunay L, Souron V, Lafosse L, et al. Analgesia after arthroscopic rotator cuff repair: subacromial versus interscalene continuous infusion of ropivacaine. Reg Anesth Pain Med 2005;30:117–22.
- [31] Fredrickson M, Krishnan S, Chen C. Postoperative analgesia for shoulder surgery: a critical appraisal and review of current techniques. Anaesthesia 2010;65:608–24.
- [32] Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesthesia & Analgesia 1993;77:1048–56.
- [33] Hurley RW, Chatterjea D, Feng MR, et al. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology 2002;97:1263–73.
- [34] Agarwal A, Gautam S, Gupta D, et al. Evaluation of a single preoperative dose of pregabalin for attenuation of postoperative pain after laparoscopic cholecystectomy. Br J Anaesth 2008;101:700–4.
- [35] Mathiesen O, Møiniche S, Dahl JB. Gabapentin and postoperative pain: a qualitative and quantitative systematic review, with focus on procedure. BMC Anesthesiol 2007;7:6.
- [36] Turan A, Kaya G, Karamanlioglu B, et al. Effect of oral gabapentin on postoperative epidural analgesia. Br J Anaesth 2006;96:242–6.
- [37] Tuncer S, Bariskaner H, Reisli R, et al. Effect of gabapentin on postoperative pain: a randomized, placebo-controlled clinical study. The Pain Clinic 2005;17:95–9.
- [38] Turan A, White PF, Karamanlioglu B, et al. Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. Anesth Analg 2007;104:97–101.
- [39] Ho K-Y, Gan TJ, Habib AS. Gabapentin and postoperative pain a systematic review of randomized controlled trials. Pain 2006;126: 91–101.
- [40] Pandey CK, Navkar DV, Giri PJ, et al. Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study. J Neurosurg Anesthesiol 2005;17:65–8.
- [41] Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995;18:469–81.